Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)

Gao, B; Gao, WG; Wan, HL; Xu, FM; Zhou, R; Zhang, X; Ji, QH

Ji, QH (通讯作者)，Air Force Mil Med Univ, Xijing Hosp, 15 West Changle Rd, Xian 710032, Shanxi, Peoples R China.

DIABETES OBESITY & METABOLISM, 2022; 24 (6): 991

Abstract

Aims To demonstrate the noninferiority of alogliptin to acarbose, in terms of antidiabetic efficacy, in Chinese people with uncontrolled type 2 diabet......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索